Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity starts Made Tech at 'buy'

(Sharecast News) - Canaccord Genuity initiated coverage on IT services firm Made Tech with a 55.0p target price and 'buy' rating on Thursday, stating the stock was "back for good". Canaccord Genuity said Made Tech was a "nimble UK public sector DX market share gainer" that has organically grown sales ten times over the last six years, materially outperforming its end-market and most peers.

The Canadian bank stated that following some "growing pains" and a weak end-market in 2024, Made Tech has now "firmly found its footing again", with Thursday's FY25 trading update pointed to a sustained return to double-digit organic growth whilst beating consensus sales, profit and net cash expectations for the year, continuing the pattern of the last 12 months.

"Our estimates assume a likely conservative 9% FY25-27 sales compound annual growth rate, well ahead of UK IT/tech-services peers, with end-FY25 backlog growth of 52% providing good visibility here. Due to expected improvements in gross margins (fewer contractors, higher utilisation rates) and operating leverage, we forecast EBIT margins to improve from the current ~5% to ~7% by FY27, driving a sector-leading FY25-27E EPS CAGR of 22%," said Canaccord Genuity.

"Assuming Made Tech can continue to gain share of its +£3.0bn TAM and penetrate more high-spending government departments, such as Ministry of Defence, Department of Work and Pensions, His Majesty's Revenue and Customs and others, it could continue to grow at mid-teens percentage. On this trajectory, £100.0m in run-rate sales and £10.0m EBIT by 2030 would be a distinct possibility. On our estimates, this could drive the shares to 100.0p, more than three times current levels."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.